Table 1 Baseline demographic and disease characteristics of 218 patients with rheumatoid arthritis
Demographic variablesSequential monotherapy (group 1)(n = 55)Step-up combination therapy (group 2)(n = 46)Initial combination with prednisone (group 3)(n = 65)Initial combination with infliximab (group 4)(n = 52)
Age, years (n = 218)*55 (13)54 (14)55 (14)54 (15)
Caucasian race, % (n = 218)95949594
Women, % (n = 218)71836269
Postmenopausal, % (n = 153)69626465
Age at menopause, years*48 (5)47 (5)46 (5)48 (6)
BMI, kg/m2 (n = 216)*26 (4)25 (4)25 (4)25 (4)
Current smoker, % (n = 218)47353527
    Cigarettes/day†12 (6–23)10 (10–19)15 (7–24)14 (7–18)
Previous clinical fractures >30 years, % (n = 218)9151712
    Postmenopausal fractures, %0986
Familial osteoporosis, % (n = 218)15151521
Disease-related variables
    Symptom duration, weeks (n = 218)†18 (12–55)24 (15–41)22 (13–56)23 (13–38)
    Positive IgM RF, % (n = 218)64656362
    DAS (n = 218)*4.6 (0.9)4.5 (0.9)4.4 (0.8)4.2 (0.9)
    CRP levels (n = 218)†29 (10–65)18 (7–38)21 (10–61)33 (7–36)
    HAQ score, 0–3 scale (n = 218)*1.5 (0.7)1.5 (0.6)1.4 (0.6)1.2 (0.7)
    Total SHS, 0–4484.0 (1.3–7.8)2.8 (1.0–7.5)3.5 (1.5–7.3)4.3 (1.0–9.5)
    scale (n = 216)*†6.0 (6.7)5.8 (7.7)4.9 (5.0)6.2 (6.6)
    Total erosions, 0–280 scale*†2.0 (1.0–4.0)1.3 (0.0–4.1)1.5 (0.5–4.0)2.5 (0.5–6.8)
3.0 (3.3)3.2 (4.6)2.8 (3.4)4.0 (4.6)
    Total JSN, 0–168 scale*†1.0 (0.0–4.0)1.3 (0.0–4.5)1.5 (0.0–3.3)1.5 (0.0–3.0)
3.0 (4.2)2.6 (3.6)2.1 (2.5)2.2 (3.0)
Erosive disease, % (n = 216)77616869
Calcium intake, mg/day (n = 218)*875 (337)889 (369)930 (326)881 (350)
25(OH)vitamin D level, nmol/l (n = 175)*53 (26)47 (27)50 (25)60 (31)
  • BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; HAQ, health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS, Sharp–van der Heijde score.

  • *Mean (SD).

  • †Median (interquartile range).